Literature DB >> 27723376

Ketamine up-regulates a cluster of intronic miRNAs within the serotonin receptor 2C gene by inhibiting glycogen synthase kinase-3.

Steven F Grieco1,2, Dmitry Velmeshev1,2, Marco Magistri1,2, Hagit Eldar-Finkelman3, Mohammad A Faghihi1,2, Richard S Jope1,2, Eleonore Beurel1,2.   

Abstract

OBJECTIVES: We examined mechanisms that contribute to the rapid antidepressant effect of ketamine in mice that is dependent on glycogen synthase kinase-3 (GSK3) inhibition.
METHODS: We measured serotonergic (5HT)-2C-receptor (5HTR2C) cluster microRNA (miRNA) levels in mouse hippocampus after administering an antidepressant dose of ketamine (10 mg/kg) in wild-type and GSK3 knockin mice, after GSK3 inhibition with L803-mts, and in learned helpless mice.
RESULTS: Ketamine up-regulated cluster miRNAs 448-3p, 764-5p, 1264-3p, 1298-5p and 1912-3p (2- to 11-fold). This up-regulation was abolished in GSK3 knockin mice that express mutant constitutively active GSK3. The GSK3 specific inhibitor L803-mts was antidepressant in the learned helplessness and novelty suppressed feeding depression-like behaviours and up-regulated the 5HTR2C miRNA cluster in mouse hippocampus. After administration of the learned helplessness paradigm mice were divided into cohorts that were resilient (non-depressed) or were susceptible (depressed) to learned helplessness. The resilient, but not depressed, mice displayed increased hippocampal levels of miRNAs 448-3p and 1264-3p. Administration of an antagonist to miRNA 448-3p diminished the antidepressant effect of ketamine in the learned helplessness paradigm, indicating that up-regulation of miRNA 448-3p provides an antidepressant action.
CONCLUSIONS: These findings identify a new outcome of GSK3 inhibition by ketamine that may contribute to antidepressant effects.

Entities:  

Keywords:  Ketamine; depression; glycogen synthase kinase-3; hippocampus; microRNA

Mesh:

Substances:

Year:  2016        PMID: 27723376      PMCID: PMC5386835          DOI: 10.1080/15622975.2016.1224927

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  46 in total

Review 1.  Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases.

Authors:  Eleonore Beurel; Steven F Grieco; Richard S Jope
Journal:  Pharmacol Ther       Date:  2014-11-27       Impact factor: 12.310

2.  Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice.

Authors:  E Beurel; L Song; R S Jope
Journal:  Mol Psychiatry       Date:  2011-04-19       Impact factor: 15.992

3.  Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta.

Authors:  R Silva; A R Mesquita; J Bessa; J C Sousa; I Sotiropoulos; P Leão; O F X Almeida; N Sousa
Journal:  Neuroscience       Date:  2007-12-23       Impact factor: 3.590

4.  Acute increases in plasma mammalian target of rapamycin, glycogen synthase kinase-3β, and eukaryotic elongation factor 2 phosphorylation after ketamine treatment in three depressed patients.

Authors:  Chun Yang; Zhi-qiang Zhou; Zhi-qin Gao; Jin-yun Shi; Jian-Jun Yang
Journal:  Biol Psychiatry       Date:  2012-08-09       Impact factor: 13.382

5.  Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice.

Authors:  Angelo O Rosa; Manuella P Kaster; Ricardo W Binfaré; Susana Morales; Ester Martín-Aparicio; Maria Luisa Navarro-Rico; Ana Martinez; Miguel Medina; Antonio G García; Manuela G López; Ana Lúcia S Rodrigues
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-06-25       Impact factor: 5.067

6.  Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus.

Authors:  Lêda S B Garcia; Clarissa M Comim; Samira S Valvassori; Gislaine Z Réus; Luciana M Barbosa; Ana Cristina Andreazza; Laura Stertz; Gabriel R Fries; Elaine Cristina Gavioli; Flavio Kapczinski; João Quevedo
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-08       Impact factor: 5.067

7.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

8.  Blocked inhibitory serine-phosphorylation of glycogen synthase kinase-3alpha/beta impairs in vivo neural precursor cell proliferation.

Authors:  Tae-Yeon Eom; Richard S Jope
Journal:  Biol Psychiatry       Date:  2009-06-11       Impact factor: 13.382

9.  Glycogen synthase kinase-3 in the etiology and treatment of mood disorders.

Authors:  Richard Scott Jope
Journal:  Front Mol Neurosci       Date:  2011-08-09       Impact factor: 5.639

10.  miRIAD-integrating microRNA inter- and intragenic data.

Authors:  Ludwig Christian Hinske; Gustavo S França; Hugo A M Torres; Daniel T Ohara; Camila M Lopes-Ramos; Jens Heyn; Luiz F L Reis; Lucila Ohno-Machado; Simone Kreth; Pedro A F Galante
Journal:  Database (Oxford)       Date:  2014-10-06       Impact factor: 3.451

View more
  5 in total

Review 1.  Neuropathology of suicide: recent findings and future directions.

Authors:  P-E Lutz; N Mechawar; G Turecki
Journal:  Mol Psychiatry       Date:  2017-07-11       Impact factor: 15.992

2.  Preclinical toxicological study of prolonged exposure to ketamine as an antidepressant.

Authors:  Julia Zaccarelli-Magalhães; André Rinaldi Fukushima; Natalia Moreira; Marianna Manes; Gabriel Ramos de Abreu; Esther Lopes Ricci; Paula A Faria Waziry; Helenice de Souza Spinosa
Journal:  Pharmacol Rep       Date:  2019-12-20       Impact factor: 3.024

Review 3.  miRNAs in depression vulnerability and resilience: novel targets for preventive strategies.

Authors:  Nicola Lopizzo; Valentina Zonca; Nadia Cattane; Carmine Maria Pariante; Annamaria Cattaneo
Journal:  J Neural Transm (Vienna)       Date:  2019-07-26       Impact factor: 3.575

Review 4.  Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.

Authors:  Kenji Hashimoto
Journal:  Psychiatry Clin Neurosci       Date:  2019-07-11       Impact factor: 5.188

5.  miR-98-5p plays a critical role in depression and antidepressant effect of ketamine.

Authors:  Chaoli Huang; Yuanyuan Wang; Zifeng Wu; Jiali Xu; Ling Zhou; Di Wang; Ling Yang; Bin Zhu; Guiquan Chen; Cunming Liu; Chun Yang
Journal:  Transl Psychiatry       Date:  2021-09-03       Impact factor: 6.222

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.